Corcept Therapeutics Holds Annual Stockholder Meeting

An announcement from Corcept Therapeutics ( (CORT) ) is now available.

On June 10, 2025, Corcept Therapeutics held its annual meeting of stockholders, where key decisions included the election of nine directors, ratification of Ernst & Young LLP as the independent accounting firm for 2025, and approval of executive compensation. These decisions are significant for the company’s governance and operational oversight, impacting its strategic direction and stakeholder relations.

The most recent analyst rating on (CORT) stock is a Buy with a $115.00 price target. To see the full list of analyst forecasts on Corcept Therapeutics stock, see the CORT Stock Forecast page.

Spark’s Take on CORT Stock

According to Spark, TipRanks’ AI Analyst, CORT is a Outperform.

Corcept Therapeutics exhibits a strong financial foundation and positive growth outlook, primarily driven by robust revenue growth and favorable earnings call outcomes. Technical analysis suggests some caution due to short-term bearish signals, while valuation indicates the stock may be overvalued, which could limit upside potential. Overall, the company holds a solid position but faces some operational and legal risks.

To see Spark’s full report on CORT stock, click here.

More about Corcept Therapeutics

Corcept Therapeutics Incorporated operates in the pharmaceutical industry, focusing on the development and commercialization of drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders. The company is known for its work on cortisol modulation therapies.

Average Trading Volume: 1,689,140

Technical Sentiment Signal: Buy

Current Market Cap: $7.43B

For a thorough assessment of CORT stock, go to TipRanks’ Stock Analysis page.